Welcome to the e-CCO Library!

P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Ho1, T. Sipponen1,2*, T.S. Jokiranta1,3

Created: Thursday, 21 February 2019, 9:14 AM
P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Samaan1, G. Cunningham1, G. Tamilarasan1, K. Rawstron2, K. Hawash2, L. Beltran2, S. Ray1, J. Mawdsley1, S. Anderson1, J. Sanderson1, Z. Arkir2, P. Irving1

Created: Thursday, 30 January 2020, 10:12 AM
P723: Comparison of the Persistence Rates of Biologic Agents in Paediatric Crohn's Disease Patients (Japanese Paediatric IBD Registry Study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nishida, D.(1);Ishige, T.(2);Arai, K.(3);Shimizu, H.(3);Iwama, I.(4);Nambu, R.(4);Kunisaki, R.(1);Yaguchi, K.(1)*;Mizuochi, T.(5);Murakoshi, T.(6);Saito, T.(7);Kato, S.(8);Kudo, T.(9);Iwata, N.(10);Inoue, M.(11);Yodoshi, T.(12);Hagiwara, S.I.(13);Toita, N.(14);Tajiri, H.(15);Mochizuki, T.(16);Kakuta, F.(17);Kumagai, H.(18);Noguchi, A.(19);Sasaki, M.(20);Nishimata, S.(21);Aomatsu, T.(22);Hirano, Y.(3);Shimizu, T.(23);
Created: Friday, 14 July 2023, 11:12 AM
P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Reenaers1*, A. Cremer2, O. Dewit3, B. de Vroey4, W. Van Moerkercke5, P. Bossuyt6, V. Muls7, J. Imschoot8, S. Block8, A. Hantson8, P. Van Hootegem9

Created: Thursday, 21 February 2019, 9:14 AM
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. E. Detlie*1,2, J. C. Lindstrøm3, M. E. Jahnsen1, E. Finnes4, H. Zoller5, B. Moum4,6, J. Jahnsen1,2

Created: Friday, 22 February 2019, 9:41 AM
P723: SexIDI study – sexual satisfaction in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roseira J.*1, Tavares de Sousa H.1, Marreiros A.2, Estevens D.3, Queiros P.1, Vaz A.M.1, Gago T.1, Contente L.1, Guerreiro H.1

Created: Wednesday, 20 February 2019, 10:36 AM
P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Ungar1,2, Z. Ben-Shatach1,2, T. Ziv-Baran2,3, E. Fudim1,2, M. Yavzori1,2, O. Picard1,2, L. Selinger1,2, B. Weiss2,4, U. Kopylov1,2, R. Eliakim1,2, S. Ben-Horin1,2

Created: Thursday, 30 January 2020, 10:12 AM
P724: Appendectomy is not a treatment option for ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Myrelid P.1,2, Landerholm K.*3,4, Nordenvall C.5,6, Pinkney T.D.7, Andersson R.E.2,3

Created: Wednesday, 20 February 2019, 10:36 AM
P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Strik1*, W. van de Vrie2, J. Bloemsaat-Minekus3, M. Nurmohamed4, P. Bossuyt5, A. Bodelier6, T. Rispens7, Y. van Megen3, G. D'Haens1

Created: Thursday, 21 February 2019, 9:14 AM
P724: Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World Experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Krugliak Cleveland, N.(1)*;Friedberg, S.(1);Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Rubin, D.T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Card*1, R. Ungaro2, F. Bhayat3, A. Blake3, G. Hantsbarger3, S. Travis4

Created: Friday, 22 February 2019, 9:41 AM
P725 Trends in biologic use prior to resective surgery for inflammatory bowel disease: A Canadian population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Chopra1, E. Kennedy2, A.V. Weizman1, A. Tennakoon3, L.E. Targownik1

Created: Thursday, 30 January 2020, 10:12 AM
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. McGettigan*1, C. Mc Shane2, O. Mc Carthy1, A. Keogh1, D. Kevans2, E. Slattery1

Created: Friday, 22 February 2019, 9:41 AM
P725: Ileal pouch excision: A contemporary observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Worley1,2*, D. Patsouras3, K. Sahnan1,3, S. Adegbola1,3, H. Mahmood3, O. Faiz1,3, S. Clark1,3

Created: Thursday, 21 February 2019, 9:14 AM
P725: Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van De Pol, N.(1)*;van der Woude, C.J.(1);Vis, M.(2);van Doorn, M.B.A.(3);Derikx, L.A.A.P.(1);Molendijk, I.(1);de Vries, A.C.(1);
Created: Friday, 14 July 2023, 11:12 AM
P725: The impact of an integrated model of care for patients with inflammatory bowel disease in Canada
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peña-Sánchez J.N.*1, Lix L.M.2, Teare G.F.3, Li W.3, Fowler S.A.4, Jones J.L.5

Created: Wednesday, 20 February 2019, 10:36 AM
P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Bokemeyer1, S. Plachta-Danielzik2, C. Sobotzki3, W. Mohl4, M. Hoffstadt5, T. Krause6, R. Atreya7, M. von der Ohe8, U. Graefe9, L. Trentmann10, M. Eisold11, A. Linde9, S. Franzenburg13, M. Moser13, P. Hartmann14, S. Schreiber15, German IBD Study Group (GISG)

Created: Thursday, 30 January 2020, 10:12 AM
P726: Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ollech, J.(1)*;Yanai, H.(2);Avni Biron, I.(2);Dotan, I.(2);
Created: Friday, 14 July 2023, 11:12 AM
P726: High mortality risk after first hospital admission for inflammatory bowel disease: a nationwide registry linkage study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Opstelten J.*1, Vaartjes I.2, Siersema P.3, Bots M.2, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P726: Metalloproteinase 3: A new marker for assessing loss of response to infliximab in IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Barberio1*, R. D'Incà2, M. Dalla Gasperina1, S. Facchin1, L. Digiglio1, R. Cardin1, G. Lorenzon1, A. Rigo1, G.C. Sturniolo1

Created: Thursday, 21 February 2019, 9:14 AM